Traditional Chinese medicine granules for treating chronic hepatitis and forepart hepetocirrhosis and preparation method thereof

Abstract

The invention discloses granules for treating chronic hepatitis and forepart hepetocirrhosis. The granules are prepared from the following substances in parts by weight of 14-18 parts astragalus mongholicus, 15-18 parts of codonopsis pilosula, 14-18 parts of white atractylodes rhizome, 15-18 parts of radices trichosanthis, 22-26 parts of rhizoma anemarrhenae, 15-17 parts of rhizoma sparganii, 15-18 parts of curcuma zedoary, 14-17 parts of endothelium corneum gigeriae galli, 20-25 parts of radix paeoniae alba, 22-26 parts of tuckahoe, 22-25 parts of angelica sinensis, 47-49 parts of root of red-rooted salvia, and 9-11 parts of leech. The granules disclosed by the invention can protect hepatocyte, reduces degeneration, necrosis and immune injury of the hepatocyte, promotes degradation of a collagenous fiber, adjusts cellular immune function, and reduces inflammation and necrosis of the hepatocyte. The traditional Chinese medicine granules are wide in the crowd in clinical use, long in application time, good in clinical curative effect and free of bad reaction.

Description

technical field [0001] The invention relates to the field of traditional Chinese medicine preparations, in particular to a traditional Chinese medicine for treating chronic hepatitis and early liver cirrhosis. Background technique [0002] Chronic hepatitis refers to a chronic inflammatory disease of the liver caused by various reasons with a course of more than half a year. Most of them are transformed from acute viral hepatitis. Due to the disorder of the body's own immune function, long-term use of drugs that damage the liver and the body's allergy to drugs, alcoholism, lack of certain enzymes, and metabolic disorders can all lead to the occurrence of this disease. The clinical manifestations of traditional Chinese medicine are qi deficiency and blood stasis, distending pain in the flank, discomfort, lack of food, and fatigue. The incidence of chronic hepatitis has risen sharply. Statistics show that about 20% of patients with chronic hepatitis turn into liver cirrhosis,...

AI Technical Summary

Problems solved by technology

[0004] There are many clinical treatment methods for chronic hepatitis and early liver cirrhosis. Although some western medicines and chemical medicines can play a certain therapeutic effect to a certain extent, they have obvious toxic and side effects, and long-term use of large amounts can lead to leukopenia

For example, the commonly used western medicine lamivudine can only relieve hepatitis B virus, but cannot really remove hepatitis B virus, and cannot treat hepatitis B fundamentally. Long-term use is prone to drug resistance. Stopping the drug will lead to repeated outbreaks of hepatitis B disease, not only can not be cured Hepatitis B will also aggravate the damage to the liver and increase the severity of the disease, and the use of lamivudine to treat hepatitis B generally causes hepatitis B virus to mutate after more than half a year, and the mutation rate of hepatitis B virus increases over time

Images